FDA advisory committee

Pfizer
Pharma

FDA advisors unanimously reject Pfizer's Talzenna expansion bid

Pfizer's Talzenna is the latest victim in a two-day FDA advisory committee meeting that put multiple drugmakers' cancer med data through the wringer.
Fraiser Kansteiner May 22, 2025 10:20am
Darzalex Faspro

FDA advisors back Darzalex as treatment for early myeloma

May 21, 2025 8:52am
FDA stop sign

FDA leaders push for more US enrollment in cancer trials

May 20, 2025 12:52pm
FDA

J&J, Pfizer and Roche face FDA questions over data applicability

May 16, 2025 3:52pm
FDA conference hall

FDA to host first oncology adcomm meeting under Makary

May 8, 2025 11:35am
Cancelled

FDA cancels adcomm for Cabometyx in neuroendocrine tumors

Jan 10, 2025 9:46am